$3.50
-1.1%Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Strong net margins indicate efficient operations and favorable tax/interest management.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
NAGE • NASDAQ
| Niagen Bioscience Inc Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||||||
129.4M | 99.6M | 83.6M | 72.1M | 67.4M | 59.3M | 46.3M | 31.6M | 21.2M | 21.7M | 17.9M | 15.3M | 10.2M | 11.6M | 8.1M | 7.6M | 5.8M | 4.5M | 0.0 | |
GROSS PROFIT | |||||||||||||||||||
(46.2M) | (38M) | (32.8M) | (29.3M) | (26M) | (24M) | (20.5M) | (15.5M) | (10.7M) | (11.3M) | (10.4M) | (10M) | (7M) | (9.3M) | (5.6M) | (4.6M) | (3.7M) | (3.3M) | (0.0) | |
83.2M | 61.6M | 50.8M | 42.8M | 41.5M | 35.3M | 25.8M | 16.1M | 10.5M | 10.4M | 7.5M | 5.3M | 3.1M | 2.3M | 2.5M | 2.9M | 2M | 1.2M | 0.0 | |
OPERATING INCOME | |||||||||||||||||||
(68.9M) | (53.9M) | (56.4M) | (61.4M) | (68.6M) | (55.1M) | (57.1M) | (49.2M) | (26.9M) | (13.3M) | (9.6M) | (10.6M) | (7.5M) | (13.9M) | (10.3M) | (5M) | (2.9M) | (3.3M) | (38.4K) | |
(62.6M) | (47.8M) | (51.4M) | (56.6M) | (64.7M) | (51.7M) | (52.5M) | (43.7M) | (22.1M) | (10.8M) | (8.7M) | (10M) | (7.3M) | (13.9M) | (10.3M) | (5M) | (2.9M) | (3.3M) | (38.4K) | |
(6.3M) | (6M) | (5M) | (4.8M) | (3.8M) | (3.4M) | (4.4M) | (5.5M) | (4M) | (2.5M) | (891.6K) | (513.7K) | (134K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
14.3M | 7.7M | -5.6M | -18.6M | -27.1M | -19.9M | -31.3M | -33.2M | -16.4M | -2.9M | -2.1M | -5.2M | -4.4M | -11.6M | -7.9M | -2M | -892.7K | -2.1M | -38.4K | |
PRE-TAX INCOME | |||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (55K) | (71K) | (847K) | (79K) | (153K) | (371.9K) | (616K) | (158.8K) | (34.3K) | (29K) | (32.1K) | (36.1K) | (17.1K) | (70.1K) | (0.0) | |
2.1M | 1.1M | 661K | 3K | -55K | -71K | -847K | -79K | -153K | -333.3K | -612.7K | -156.8K | -33.1K | -26K | -30.7K | -34.5K | -14.8K | -40.5K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (125K) | (75K) | (746K) | (0.0) | (0.0) | (45.8K) | (45K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
3.9M | 1.1M | 661K | 2.1M | -55K | -71K | -847K | -144K | -153K | -646.4K | -566.9K | -156.8K | -33.1K | -26K | -30.7K | 2M | 892.7K | 2.1M | 38.4K | |
18.2M | 8.9M | -4.9M | -16.5M | -27.1M | -19.9M | -32.1M | -33.3M | -16.5M | -3.6M | -2.6M | -5.4M | -4.4M | -11.7M | -7.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
NET INCOME | |||||||||||||||||||
(810K) | (305K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.5K) | (0.0) | (0.0) | (0.0) | (0.0) | (2.1M) | (907.6K) | (2.1M) | (38.4K) | |
17.4M | 8.6M | -4.9M | -16.5M | -27.1M | -19.9M | -32.1M | -33.3M | -11.4M | -2.9M | -2.8M | -5.4M | -4.4M | -11.7M | -7.9M | -2.1M | -907.6K | -2.1M | -38.4K |
NAGE - Filing history and reports
No SEC filings available for NAGE
Continue your NAGE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.